Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

This is a phase I, dose-escalation study followed by a phase II study.

Inclusion Criteria:

- Recipients of first ASCT for the treatment of hematologic malignancies (multiple
myeloma, Hodgkin's and non Hodgkin's lymphoma)

- Patients must be between 100 to 180 days after ASCT

- Dasatinib use prior to ASCT is allowed

- Performance status >= 60%

- Presence of LGL clone prior to enrollment will not be an exclusion criterion if the
LGL clone is < 25% of T cell population

- Total bilirubin < 2.0 times the institutional upper limit of normal (ULN)

- Hepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =<
2.5 times the institutional ULN

- Serum creatinine < 1.5 times the institutional ULN

- Hemoglobin >= 8 g/dL

- Absolute neutrophil counts >= 1,500 cells per uL

- Platelets >= 100,000 per uL

- Patient should be able to provide signed written informed consent; before any study
procedures are performed, subjects will have the details of the study described to
them, and they will be given a written informed consent document to read; then, if
subjects consent to participate in the study, they will indicate that consent by
signing and dating the informed consent document in the presence of study personnel;
written consent will include a Health Insurance Portability and Accountability Act
(HIPAA) form according to institutional guidelines

- Patient should be able to take oral medication (dasatinib must be swallowed whole)

Exclusion Criteria:

- Patients who have evidence of disease progression before day 100 after ASCT

- Sex and reproductive status:

- Women of childbearing potential (WOCBP) who are unwilling or unable to use an
acceptable method to avoid pregnancy for the entire study period and for at least
4 weeks after the last dose of study drug

- Women who are pregnant or breastfeeding

- Women with a positive pregnancy test

- Sexually active fertile men not using effective birth control if their partners
are WOCBP

- Medical history and concurrent diseases:

- No malignancy (other than the one treated in this study) which required radiotherapy
or systemic treatment within the past 5 years

- Concurrent medical condition which may increase the risk of toxicity, including:

- Pleural or pericardial effusion of any grade at the time of screening for study

- Cardiac symptoms; any of the following should be considered for exclusion:

- Uncontrolled angina, congestive heart failure or myocardial infarction (MI)
(within 6 months)

- Diagnosed congenital long QT syndrome

- Any history of clinically significant ventricular arrhythmias (such as
ventricular tachycardia, ventricular fibrillation, or torsades de pointes)

- Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (> 450
msec)

- History of significant bleeding disorder unrelated to cancer, including:

- Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)*
Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor
VIII antibodies)

- Ongoing or recent (=< 3 months) significant gastrointestinal bleeding

- Any previous history of >= grade 3 toxicity to dasatinib

- Prohibited treatments and or therapies

- Category I drugs that are generally accepted to have a risk of causing torsades de
pointes including: (patients must discontinue drug 7 days prior to starting
dasatinib):

- Quinidine, procainamide, disopyramide

- Amiodarone, sotalol, ibutilide, dofetilide

- Erythromycin, clarithromycin

- Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide

- Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone,
halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine

- Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy
(discontinue St. Johns Wort at least 5 days before starting dasatinib)

- Patient agrees that intravenous (IV) bisphosphonates will be withheld for the first 8
weeks of dasatinib therapy due to risk of hypocalcemia

- Other exclusion criteria:

- Prisoners or subjects who are involuntarily incarcerated

- Subjects who are compulsorily detained for treatment of either a psychiatric or
physical (eg, infectious disease) illness